European Circular Bioeconomy Fund
Tuesday, 04 January 2022
ByrneWallace LLP advises the European Circular Bioeconomy Fund (ECBF) on its recent investment of $7 million in Nuritas, a Dublin-based biotechnology company revolutionizing the discovery and development of plant-based bioactive peptides. This investment forms part of Nuritas’ $45 million Series B funding round and brings to $75 million the total amount raised by the company as it eyes global expansion.
The European Circular Bioeconomy Fund (ECBF) is an impact fund initiated by the European Union in the field of bioeconomy and circular economy. The venture capital company invests in visionary European entrepreneurs who are driving the shift from a fossil-based to a bio-based economy.
The ByrneWallace LLP team who advised on this transaction included Colin Sainsbury (Partner and Head of Life Sciences Group), Catherine Dowling (Partner, Corporate & Life Science) and Daniel Holohan (Partner, Corporate).
For more information on this transaction and to view the European Circular Bioeconomy Fund’s press release click here.
